Jaguar health receives "complete" letter from fda for last of four major technical sections for the company's application for conditional approval of canalevia (crofelemer) for chemotherapy-induced diarrhea (cid) in dogs

Jaguar planning for launch of canalevia™ for cid in dogs this december canalevia is the first and only oral plant-based prescription drug candidate for cid in dogs san francisco, ca / accesswire / september 23, 2021 / jaguar health, inc. (nasdaq:jagx) today announced that it was informed on september 21, 2021 by the fda's center for veterinary medicine (cvm) that the target animal safety (tas) technical section of the company's application for conditional approval of canalevia for chemotherapy-induced diarrhea (cid) under the minor use/minor species (mums) section of the minor use and minor species animal health act of 2004 has been deemed "complete". the tas section - the last of the four major technical sections of jaguar's application - describes testing undertaken to show that a drug candidate is safe for use under the conditions for which the drug will be prescribed following its approval.
JAGX Ratings Summary
JAGX Quant Ranking